


PAAB Preclearance Review Mechanism: Audit Report

Summary

July 2015




Overview

- Introduction
- Audit Objectives& Methodology
- Results Overview
 (overall operational performance;
 level of consistency within the system)
- Next Steps





About PAAB



PAAB Vision: Trusted healthcare product communication that promotes optimal health

PAAB Mission: To provide a preclearance review that fosters trustworthy healthcare communications within a regulatory framework for the benefit of all stakeholders

PAAB Values: Integrity, competency, credibility, independence, excellence, transparency


PAAB Reach: With 13 reviewers supporting stakeholders throughout the submission process, over 7,000 first reviews are conducted each year



Context

PAAB reviews a large number of submissions across multiple channels, audiences, and stages of a product life cycle

Historical Volume of Submissions by Year




Variability:

| • | Submissions: | 6,987 | • | Therapeutic Areas: | 25 |
|---|----------------|-------|---|--------------------|----|
| • | Manufacturers: | 96 | • | APS Categories: | 26 |

Agencies:136Reviewers:13

Products: 600+

Audit Background





Recognizing that consistency in reviews has been expressed by some as a concern, PAAB took the initiative to implement an independent audit of the preclearance review system commissioned by the PAAB Board of Directors.*



^{*}The audit was completed by Integrated Pharma Services Inc., under the direction of Richard Khambatta, General Manager

PAAB Board of Directors

| Walter Rosser, MD | Chair | | |
|--------------------|---|--|--|
| Gloria Bowes | Vice Chair | | |
| Lorenzo Biondi | Treasurer | | |
| Terry Cully | Association of Medical Advertising Agencies (AMAA) | | |
| Denis Morrice | Best Medicines Coalition | | |
| Jim Hall | Canadian Association of Medical Publishers (CAMP) | | |
| Barbara Jovaisas | Canadian Pharmacists Association (CPhA) | | |
| Ken Stallman | Consumer Health Products Canada | | |
| Jeff Connell | Canadian Generic Pharmaceutical Association (CGPA) | | |
| Susan Eng | CARP | | |
| Cecile Bensimon | Canadian Medical Association (CMA) | | |
| Crawford Wright | Canada's Research-Based Pharmaceutical Companies Rx&D | | |
| Agni Shah | Consumer Council of Canada | | |
| Dr. Martin Labelle | Fédération des médecins omnipraticiens du Québec | | |
| Ex-Officio Member | Health Canada | | |





Audit Objectives

 Assess the overall operational performance within the PAAB preclearance review system

Assess the level of consistency within the PAAB preclearance review system



Methodology Overview


- The submission audit ranges from June 1, 2013 to May 31, 2014
- A thorough analysis of 50 submission samples was performed, with the goal of identifying deviations in the review process
- The escalations analysis is based on the 55 escalations that occurred between January 1, 2014 to October 31, 2014
- The full audit report was presented by Integrated Pharma Services Inc. to the PAAB Board of Directors on April 24, 2015



Audit Results:
Overall Operational
Performance

Results: Overall Operational Performance Reviews

- Results showed that submissions are being processed efficiently and within established timelines
- 61.2% of all submissions in the given audit period were approved within 1 or 2 revisions




- (+) 14% of submissions saw the reviewer miss identifying issue(s) in the first review
- 24% of submissions saw the reviewer identifying an issue(s) because of a client-based change, new document(s), or translation(s)

^{*}These figures do not include prescreening by PAAB to ensure submissions meet a minimum standard of completeness before being assigned to a Reviewer.

Results: Overall Operational Performance Revisions

1 The average number of revisions per submission by reviewer was 2.39

Average Number of Revisions per Submission by Reviewer




Note that there are a variety of factors that can impact these results, including the complexity of the APS and subject matter being managed by each reviewer

Results: Overall Operational Performance Escalations

⊕ The volume of client escalations/appeals was minimal (<1% of total submissions)
</p>

PAAB Escalations: Broken Down by Relative Percentage






Results: Overall Operational Performance Escalations cont'd

• 87% of escalations resulted in PAAB's ruling being sustained, a solution being found, or the APS being withdrawn








Results: Overall Operational Performance Escalations by Agency

⊕ 13.9% of agencies submitted 1 or more escalations, with an average of 2.89 escalations per agency which submitted

Number of Escalations by Agency




Results: Overall Operational Performance Escalations by Reviewer

There was an average of 3.7 escalations per reviewer

Number of Escalations by Reviewer

Period: 01-Jan-14 to 31-Oct-2014 (n=55)





Audit Results: Level of Consistency Within the System

Results: Level of Consistency Within the System

- The consistency audit could not identify any definitive examples of inconsistencies in the Reviewer decisionmaking process
 - The current system does not provide a formal means to document potential inconsistencies in Reviewers' decisions





Level of Consistency Within the System Additional Information/Solutions

Additional information will be required in the form of specific examples for PAAB to more thoroughly investigate the level of consistency within the system*

Potential solutions to help obtain this information are being considered, and details will be disseminated as proposed solutions are confirmed

^{*}It is recognized that despite the audit being unable to identify any definitive examples of inconsistencies in the Reviewer decision-making process, previous surveys and feedback indicate that consistency (specifically between-reviewer consistency) remains a concern of stakeholders



Level of Consistency Within the System What Is Already Being Done

PAAB makes significant effort to support reviewers to promote a consistent decision-making process. The primary tools and means currently employed include:

| Defined Therapeutic Teams | OneNote Database | PAAB System | Reviewer Training | Team Meetings |
|--|---|---|---|---|
| Specialized teams to focus on specific therapeutic areas, rather than reviewers working across all therapeutic areas | A very comprehensive searchable database which provides detailed examples of previous PAAB decisions and rationales | A searchable resource, enabling reviewers to examine a variety of related reference materials quickly and efficiently | Once a new reviewer is hired, he/she goes through extensive training and works closely with other reviewers to develop the required level of competency | Used as an opportunity to train reviewers, discuss new and current issues, and facilitate consultations between reviewers and the Deputy Commissioner |



We Want to Hear From You!

- Your thoughts are important to us we encourage you to reach out with compliments or concerns
 - Let us know what you think we're doing well and where you think we could improve
 - Specific examples always help us better take action, so thank you in advance for sharing them when you can
- We will carefully consider all feedback
- We will remain committed to ensuring that the PAAB Code is interpreted accurately, and will strive for consistent interpretation among reviewers and across submissions



Contact Us

Contact us at info@paab.ca
We're here to help you get to yes

Pharmaceutical Advertising Advisory Board 300-1305 Pickering Parkway, Pickering, Ontario L1V 3P2, Canada

Phone: +1 (905) 509-2275

Ray Chepesiuk
PAAB Commissioner
RayC@paab.ca

Patrick Massad
PAAB Deputy Commissioner
PatrickM@paab.ca

